BBIO News and Press, BridgeBio Pharma Inc. From 03/08/23

2023-03-08 11:54:50 ET During Wednesday's midday trading, the major U.S. equity indexes were mixed, as Wall Street tried to recover following hawkish comments by Federal Reserve Chairman Jerome Powell the day before. Looking at the individual stocks, Korn Ferry ( NYSE: KFY )...

2023-03-08 07:08:52 ET BridgeBio Pharma ( NASDAQ: BBIO ) has priced its public offering of ~8.8M common shares at $17.00/share, for gross proceeds of ~$150M. Underwriters' over-allotment is an additional ~1.3M shares. Closing date is March 10. All of the shares in ...

PALO ALTO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 7, 2023 of an underwritten public offering of 8,823,5...

2023-03-07 08:15:48 ET Summary Markets sent BridgeBio sharply higher after the company posted clinical Phase 2 results for infigratinib. After the close, BBIO announced a stock sale that would raise $150 million. Price target implying nearly 45% in upside discussed. ...

2023-03-06 18:08:08 ET BridgeBio Pharma ( NASDAQ: BBIO ) reached a 52-week high Monday of $19.39 and closed up 52% due to positive mid-stage results on achondroplasia candidate infigratinib. Data showed 80% of children at six months were responders. BridgeBio ( B...

2023-03-06 17:51:13 ET The major U.S. equity averages posted a mixed performance on Monday, holding steady after the gains recorded at the end of last week. Wall Street looked ahead to an appearance by Federal Reserve Chair Jerome Powell, who is scheduled to appear before Congress starting ...

2023-03-06 16:27:08 ET BridgeBio Pharma ( NASDAQ: BBIO ) said it had begun an underwritten public offering of $150M of shares of its common stock. BridgeBio also expects to grant the underwriters a 30-day option to purchase up to an additional $22.5M of shares. Goldman Sac...

PALO ALTO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $150 million of s...

2023-03-06 14:32:00 ET The stock market got off to a solid start on Monday, although there was a considerable disparity among different kinds of stocks. Small-cap indexes were down sharply, but the Dow Jones Industrial Average (DJINDICES: ^DJI) was higher by about a quarter-percent ...

2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...